Correction to: A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation (Oncogene, (2016), 35, 33, (4368-4378), 10.1038/onc.2015.504);A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation

Oncogene

Volumn 35, Issue 33, 2016, Pages 4368-4378

  Grassilli, E ^a,b   Pisano, F ^a,b   Cialdella, A ^a,b   Bonomo, S ^a   Missaglia, C ^a   Cerrito, M G ^a   Masiero, L ^a   Ianzano, L ^a   Giordano, F ^a   Cicirelli, V ^a   Narloch, R ^a   D'Amato, F ^c   Noli, B ^c   Ferri, G L ^c   Leone, B E ^a   Stanta, G ^d   Bonin, S ^d   Helin, K ^e,f,g   Giovannoni, R ^a   Lavitrano, M ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b BiOnSil Srl   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE P65; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; 5' UNTRANSLATED REGION; AGAMMAGLOBULINAEMIA TYROSINE KINASE; HNRNPK PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

5' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER CELL LINE; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; INTERNAL RIBOSOME ENTRY SITE; ONCOGENE; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; CELL TRANSFORMATION; COLON TUMOR; ENZYMOLOGY; GENETICS; MAPK SIGNALING; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN K; HUMANS; MAP KINASE SIGNALING SYSTEM; PROTEIN ISOFORMS; PROTEIN-TYROSINE KINASES; RAS PROTEINS;

EID: 84955618214     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-024-03037-w     Document Type: Erratum

References (37)

1. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993; 261: 358-361.
2. Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009; 228: 58-73.
3. Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol 2014; 3: 4-10.
4. Feldhahn N, Ro P, Soh BN, Liedtke S, Sprangers M, Klein F et al. Deficiency of Brutons tyrosine kinase in B cell precursor leukaemia cells. Proc Natl Acad Sci USA 2005; 102: 13266-13271.
5. Li T, Tsukada S, Satterthwaite A, Havlik MH, Park H, Takatsu K et al. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity 1995; 2: 451-460.
6. Park H, Wahl MI, Afar DE, Turck CW, Rawlings DJ, Tam C et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 1996; 4: 515-525.
7. Dingjan GM, Maas A, Nawijn MC, Smit L, Voerman JS, Grosveld F et al. Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase. EMBO J 1998; 17: 5309-5320.
8. Salamov AA, Nishikawa T, Swindells MB. Assessing protein coding region integrity in cDNA sequencing projects. Bioinformatics 1998; 14: 384-390.
9. Komar AA, Mazumder B, Merrick WC. A new framework for understanding IRESmediated translation. Gene 2012; 502: 75-86.
10. Bomsztyk K, Denisenko O, Ostrowski J. hnRNP K: one protein multiple processes. Bioessays 2004; 26: 629-638.
11. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006; 95: 921-927.
12. Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM et al. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol 2001; 3: 325-330.
13. Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006; 107: 2507-2516.
14. Marash L, Liberman N, Henis-Korenblit S, Sivan G, Reem E, Elroy-Stein O et al. DAP5 promotes cap-independent translation of Bcl-2 and CDK1 to facilitate cell survival during mitosis. Mol Cell 2008; 30: 447-459.
15. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 2005; 280: 10964-10973.
16. Didiot MC, Hewett J, Varin T, Freuler F, Selinger D, Nick H et al. Identification of cardiac glycoside molecules as inhibitors of c-Myc IRES-mediated translation. J Biomol Screen 2013; 1: 407-419.
17. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010; 10: 254-266.
18. Guha M. Imbruvica-next big drug in B-cell cancer-approved by FDA. Nat Biotechnol 2014; 32: 113-115.
19. Burger JA. Brutons tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep 2014; 9: 44-49.
20. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM et al. Mechanism of activation of a human oncogene. Nature 1982; 300: 143-148.
21. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982; 300: 149-152.
22. Taparowsky E, Suard Y, Fasano O, Shimizu K, Goldfarb M, Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 1982; 300: 762-766.
23. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 1984; 312: 71-74.
24. Eifert C, Wang X, Kokabee L, Kourtidis A, Jain R, Gerdes MJ et al. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Gene Chrom Cancer 2013; 52: 961-975.
25. Yao L, Kawakami Y, Kawakami T. The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C. Proc Natl Acad Sci USA 1994; 91: 9175-9179.
26. Kang SW, Wahl MI, Chu J, Kitaura J, Kawakami Y, Kato RM et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J 2001; 20: 5692-5702.
27. Liu W, Quinto I, Chen X, Palmieri C, Rabin RL, Schwartz OM et al. Direct inhibition of Brutons tyrosine kinase by IBtk, a Btk-binding protein. Nat Immunol 2001; 2: 939-946.
28. Spatuzza C, Schiavone M, Di Salle E, Janda E, Sardiello M, Fiume G et al. Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Brutons tyrosine kinase: evidence for three protein isoforms of IBtk. Nucleic Acids Res 2008; 36: 4402-4416.
29. Yu L, Mohamed AJ, Vargas L, Berglof A, Finn G, Lu KP et al. Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1. J Biol Chem 2006; 281: 18201-18207.
30. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/ MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012; 16: S17-S27.
31. Fang JY, Richardson BC. The MAPK signaling pathways and colorectal cancer. Lancet Oncol 2005; 6: 322-327.
32. Smith L. Post-transcriptional regulation of gene expression by alternative 5-untranslated regions in carcinogenesis. Biochem Soc Trans 2008; 36: 708-711.
33. Wurth L, Gebauer F. RNA-binding proteins, multifaceted translational regulators in cancer. Biochim Biophys Acta 2014; 1849: 881-886.
34. Spriggs KA, Stoneley M, Bushell M, Willis AE. Re-programming of translation following cell stress allows IRES-mediated translation to predominate. Biol Cell 2008; 100: 27-38.
35. Barbosa C, Peixeiro I, Romao L. Gene expression regulation by upstream open reading frames and human disease. PLoS Genet 2013; 8: e1003529.
36. Gao B, Roux PP. Translational control by oncogenic signaling pathways. Biochim Biophys Acta 2014; 1849: 753-765.
37. Pow DV, Crook DK. Extremely high titre polyclonal antisera against small neurotransmitter molecules: rapid production, characterisation and use in lightand electron-microscopic immunocytochemistry. J Neurosci Methods 1993; 48: 51-63.